How to Help Your Patients Save Money on Molnupiravir: A Provider's Guide to Savings Programs

Molnupiravir (Lagevrio) has a retail cash price that can exceed $1,100 for a 5-day treatment course. That's a significant financial burden — and cost barriers can directly prevent patients from filling their prescriptions, particularly for the high-risk populations most likely to need this drug: older adults, patients with chronic disease, transplant recipients on fixed incomes.

This guide is designed to give you — the prescribing provider — the complete picture on available cost-reduction programs, how they work, who qualifies, and how to integrate savings counseling into your prescribing workflow.

Why Cost Counseling Matters at the Point of Prescribing

Medication adherence begins with the decision to fill the prescription. For many patients, seeing a $1,000+ price tag at the pharmacy counter is enough to walk away. Proactive cost counseling at the point of prescribing — even a brief mention of available programs — significantly improves fill rates.

Given molnupiravir's time-sensitive nature (must start within 5 days of symptom onset), a delay in filling is functionally equivalent to not treating at all. Cost barriers and treatment delays are interchangeable problems.

Program 1: Merck Lagevrio Savings Coupon (Commercially Insured)

This is the most impactful savings tool for commercially insured patients:

Eligible population: Adults with commercial (private) health insurance. NOT available for Medicare, Medicaid, Tricare, or other government-funded programs.

Patient cost: As low as $10 per prescription. Maximum savings of $300 per prescription.

How to access: Patient registers and downloads the coupon at lagevrio.com/patients/coupon.

No usage limit: Patients can use this coupon for multiple fill events.

Provider action: Print or share the URL lagevrio.com/patients/coupon during the visit. For telehealth encounters, send it via secure message or patient portal. Some practices include it as a preprinted handout for any antiviral prescription.

Program 2: Merck Patient Assistance Program (Uninsured/Underinsured)

For patients without adequate insurance coverage, Merck's Patient Assistance Program (Merck Helps) can provide Lagevrio at no cost to eligible patients:

Website: merckhelps.com/LAGEVRIO

Phone: 1-800-727-5400

Application: Requires physician signature and documentation of patient income/insurance status.

Delivery: If approved, medication is shipped to the physician's office, not directly to the patient.

Important clinical note: The standard patient assistance program application and processing timeline is NOT compatible with the 5-day treatment window for acute COVID-19. This program is best used proactively for high-risk uninsured patients who you anticipate may need antiviral therapy. Consider initiating the application as part of a prevention care visit for high-risk, uninsured patients so the drug is available if needed.

Program 3: Medicare Part D Coverage

For your Medicare patients, the news is generally positive:

Most Medicare Part D plans place Lagevrio on Tier 1 (lowest cost tier), resulting in relatively low copays.

The Merck savings coupon CANNOT be used with Medicare.

Medicare patients who face high cost-sharing should be directed to the Medicare Extra Help (Low Income Subsidy) program if eligible, or to Social Security for assistance program enrollment.

The U.S. Government Patient Assistance Program (USG PAP) has provided assistance for COVID antivirals including Lagevrio for Medicare/Medicaid patients during certain periods — check CDC.gov/covid/treatment for current availability.

Program 4: Medicaid Coverage

Medicaid coverage for molnupiravir varies by state. Most Medicaid programs cover it, but prior authorization may be required in some states, or it may need to be accessed through the USG PAP program. Confirm your state Medicaid program's formulary status.

Program 5: GoodRx and Third-Party Discount Programs

GoodRx and similar discount cards can reduce the cash price for uninsured patients from $1,100 to approximately $993. While this is still a significant out-of-pocket expense, it's a meaningful reduction and available without any application process.

Important: GoodRx and manufacturer savings cards cannot generally be combined. For commercially insured patients, the Merck savings card (down to $10) is almost always a better deal than GoodRx (approximately $993).

Recommended Workflow: Cost Counseling at Point of Prescribing

Build a simple 60-second insurance screening into your antiviral prescribing workflow:

Ask: "Do you have private insurance, Medicare, Medicaid, or no insurance?"

For private insurance: Direct to Merck savings coupon (lagevrio.com/patients/coupon) → $10 copay.

For Medicare Part D: Confirm Part D plan covers Lagevrio, advise copay will be low (Tier 1 on most plans).

For uninsured: Direct to Merck Patient Assistance (merckhelps.com/LAGEVRIO or 1-800-727-5400) or GoodRx as a bridge if timing is critical.

Document cost counseling in the chart.

Helping Patients Who Can't Afford Any Option

If a patient cannot afford molnupiravir even with available savings programs and must be treated now, consider whether IV remdesivir — covered under Medicare Part B (not Part D) and often fully covered — could be an alternative. Work with your hospital system's social work team or patient advocate for additional resources.

medfinder for Your Patients: Pharmacy Access + Cost Together

Even after patients understand their cost options, they still need to find a pharmacy that has molnupiravir in stock. Direct your patients to medfinder.com/providers — a paid service that calls pharmacies near them to identify which ones have the medication available, then texts them results. Integrating this into your discharge or post-visit instructions for antiviral prescriptions can prevent treatment delays.

For more on the supply situation, see our Molnupiravir Shortage: What Providers Need to Know in 2026.

Bottom Line for Providers

Cost is a significant and underappreciated barrier to molnupiravir adherence. A brief 60-second insurance screen and savings program referral at the time of prescribing can be the difference between a patient filling their prescription and missing their treatment window entirely. Build it into your workflow today.